<DOC>
	<DOCNO>NCT02712905</DOCNO>
	<brief_summary>This open-label , dose-escalation/dose-expansion study INCB059872 subject advance malignancy . The study conduct 2 part . Part 1 ( dose escalation ) determine recommend dose ( ) INCB059872 dose expansion , base maximum tolerate dose and/or tolerate pharmacologically active dose . Part 2 ( dose expansion ) determine safety , tolerability , efficacy , PK , PD select dose ( ) .</brief_summary>
	<brief_title>An Open-Label , Dose-Escalation/Dose-Expansion Safety Study INCB059872 Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Male female subject , age 18 year old . Presence measurable disease confirm histology cytology . Must candidate potentially curative therapy standardofcare approve therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Receipt anticancer medication , anticancer therapy , investigational drug within define interval first administration study drug . Any unresolved toxicity ≥ Grade 2 previous anticancer therapy except stable chronic toxicity ( ≤ Grade 2 ) expect resolve . Laboratory medical history parameter outside Protocoldefined range . Known additional malignancy progress require active treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>small cell lung cancer ( SCLC )</keyword>
	<keyword>myelofibrosis ( MF )</keyword>
	<keyword>solid tumor , lysine-specific demethylase 1 ( LSD1 ) inhibitor</keyword>
</DOC>